Clinical Trial Search

Primary: Percentage Change in Volume of the Masseter Muscle From Baseline to 12 Weeks After Treatment With Botulinum Toxin A — 21.4 percentage reduction in masseter volume

Primary: Number of Participants Who Did HIV Testing — 36; 9 Participants

Primary: Posterior Capsule Opacification (PCO) — 3.0; 1.9 units on a scale (0-10)

Primary: Percent Change From Baseline in the Rosacea Clinical Score Card — -0.63; -0.00063; -0.65; -0.34 percent change

Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…

Primary: Visits With PrEP Dispensation to Female Study Participants Reporting Sexual Behaviors or STI Symptoms — 211 Visits

Primary: Number of TH Clients Who Received HIV Testing — 57; 250 Participants — p=<0.001

Primary: Mean Score Change in Total HIV Stigma Scale — 47.48; 47.89; 44.60; 47.32 units on a scale — p=0.083

Primary: Death — 0 Participants

Primary: Proportion Adherent to ARV and Psychotropic Medication by Electronic Monitoring System (MEMS) — 90.3; 90.0; 83.9; 90.0 percentage of taken doses — p=0.95

Primary: PrEP Prescriptions (As Measured by Chart Review) — 1; 0 Participants — p=0.51

Primary: Modified Opening Minds Scale for Health Providers (OMS-HC) — 22.92; 16.82 score on a scale

Primary: Intervention Feasibility- Number of Participants Enrolled in Each Arm — 5; 43; 44 Participants

Primary: Outcome 1: Serial HIV-1 RNA Levels in Breastmilk. — 2.74; 2.03; 1.70; 1.70 Log10 Viral load copies/ml

Primary: Adherence Rate — 20; 17 Participants — p=0.29